| Title: | Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer |
| Authors: | Ogiya, Akiko Browse this author |
| Yamazaki, Kieko Browse this author |
| Horii, Rie Browse this author →KAKEN DB |
| Shien, Tadahiko Browse this author →KAKEN DB |
| Horimoto, Yoshiya Browse this author |
| Masuda, Norikazu Browse this author |
| Inao, Touko Browse this author |
| Hosoda, Mitsuchika Browse this author →KAKEN DB |
| Ishida, Naoko Browse this author |
| Osako, Tomofumi Browse this author |
| Takahashi, Masato Browse this author |
| Endo, Yumi Browse this author →KAKEN DB |
| Miyoshi, Yuichiro Browse this author |
| Yasojima, Hiroyuki Browse this author |
| Tomioka, Nobumoto Browse this author |
| Yamashita, Hiroko Browse this author →KAKEN DB |
| Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society Browse this author |
| Keywords: | Breast cancer |
| Post-relapse survival |
| Prognosis |
| Estrogen receptor-positive |
| Endocrine therapy |
| Issue Date: | May-2017 |
| Publisher: | Springer |
| Journal Title: | Breast cancer |
| Volume: | 24 |
| Issue: | 3 |
| Start Page: | 473 |
| End Page: | 482 |
| Publisher DOI: | 10.1007/s12282-016-0730-3 |
| PMID: | 27628678 |
| Abstract: | Background: Few studies have been performed on post-relapse survival in patients with the early and late distant recurrence in estrogen receptor (ER)-positive, HER2-negative breast cancer. Methods: A total of 205 patients with the early distant recurrence and 134 patients with the late distant recurrence of ER-positive, HER2-negative breast cancer who had undergone breast surgery or neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutions. Prognostic factors for post-relapse survival in patients with the early and late recurrence were analyzed. Results: Post-relapse survival was significantly longer in patients with the late recurrence than in patients with the early recurrence. Predictive factors for post-relapse survival in patients with the early recurrence were lack of adjuvant chemotherapy, a long disease-free interval, and long durations of endocrine therapies and chemotherapies after relapse. In patients with the late recurrence, post-relapse survival was significantly improved for those individuals with one metastatic organ at relapse and individuals who were treated with the first-line and subsequent endocrine therapies for prolonged periods. Moreover, ER expression in primary breast tumors of late recurrence patients was significantly higher with a duration of the first-line endocrine therapy >6 months than in those with a duration ≤6 months. Conclusion: Predictors for prognosis after relapse differed between patients with the early and late distant recurrence. Endocrine responsiveness after relapse is a key factor for improved post-relapse survival, and it is thus important to establish whether metastatic tumors are endocrine-resistant in ER-positive, HER2-negative recurrent breast cancer. |
| Rights: | The final publication is available at link.springer.com |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/70047 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
